Seawolf Therapeutics Launches With $100M and a Sanofi Deal to Make DNA Medicines Redosable
Seawolf Therapeutics debuts with $100M and a Sanofi pact worth up to $1.2B to develop non-viral DNA medicines for bleeding disorders. What TRIDENT promises and what is unproven.
